Yu Han Pharmaceutical Co., Ltd. Shenzhen GEM starting to apply for January 25, 2011 passed by the issuance examination committee, plans to issue the corresponding total share capital after the 2009 operating income, operating income per share is only 0.93 yuan.
sponsor a senior representative of the Shenzhen-person: Share of revenues of less than 1 million, earnings per share will not be high. 2500 shares total issued share capital of 1 million shares. By John-medicine after 1 million shares total issued share capital, Han Yu Pharmaceutical recent full year 2009 operating income was 92,711,400 yuan, and its share of operating income per share is only 0.93 yuan. Once approved medicine Squire Sanders listed A-share market will become a rare sight, even lower than the scale of enterprise revenue share capital size.
Squire Sanders is specialized in the peptide pharmaceutical drug development, production and marketing enterprises, Guangdong Province, the company has engineering peptide drug research and development center. According to the official website of the company disclosed that at present the company has 33 patents, 7 national drug certification, clinical trials approval documents 5, 45 drug registration approval document, mainly used in oncology, cardiovascular, diabetes, infectious diseases and treatment of senile diseases. John prospectus disclosure in the pre-medicine information technology for the enterprise strength expressed as follows: The company independent research and development of key production technology is the leading domestic and international advanced level, are invited to participate in the drafting of the State Food and Drug Administration by the promulgation of the technical research guidelines.
Although John-medicine research and development in medicine has an advantage, but this house was originally established in 2001, pharmaceutical companies, has business income is not on a large scale. Information on the company's prospectus, in 2007, 2008, 2009 and 1 June 2010, operating income was 56,201,600 yuan, 77,359,200 yuan, 92,711,400 yuan and 51.9215 million yuan. Net profit attributable to shareholders was 15,232,200 yuan, 19,858,800 yuan, 35,365,900 yuan and 18.7989 million yuan. 2007 to 2009 operating income, net profit attributable to shareholders of the parent compound annual growth rate was 28.44%, 52.37%.
a leading investment bank in Shenzhen, a senior sponsor representatives yesterday to accept the Therefore, operating income per share accounts for less than 1 yuan IPO does not constitute a significant obstacle. However, the actual situation, for any enterprise, business income is too low will limit the scale of the scale of corporate profits; small scale enterprises operating income and revenue growth is not fast, corporate profit growth will follow is very limited. Operating income per share of less than 1 yuan, corporate earnings per share will not be high.
He also said that some companies are not sufficiently large revenue, but profit margins high. For these companies, investment banks generally will try to enable enterprises to more than 0.5 yuan in earnings per share. Only 0.5 yuan only easy to make the recommendation in issue, after all, institutions are based on earnings per share to evaluate the profitability of the business. If the share capital of the scale is too large makes the low earnings per share of listed companies will be disadvantaged. R & D capital at the helm
aphasia
mainly by the Han-woo medicine has set up a small investment of your brothers in the pre-IPO shareholding structure, it has less of your shares directly held 34.316 percent, had less strong holds 26.64%, 5.3% had less holding bin. Zeng three brothers together hold 66.26% of the Han Yu Pharmaceutical shares. John Yu medicine in the development process, Zeng Brothers Finance Party as there is not a core technical staff.
In addition, John-medicine also won the favor of domestic and foreign PE sector. December 12, 2007, Yan Yan, SAIF helm three Mauritius (China) Investment Co., Ltd. shares work Shenzhen Innovation Investment signed John-medicine. Which SAIF invested 60,625,000 yuan Han-woo medicine obtained 20.91% of the shares, invested 15 million yuan in Shenzhen Innovation Investment accounted for 4.09% shares. January 2009, Yan Yan at the helm of another investment fund TQM again John woo medicine 22,147,700 yuan. Then after a capital increase, the current holders of Squire Sanders III SAIF Pharmaceutical 19.967% stake, TQM holds a 4.51% stake in Shenzhen Innovation Investment holding 3.91% shares.
Han Feng Yu medicine is to rely on investment to lock into the core backbone. HSBC now holds 402 million shares into investment shares of Squire Sanders medicine, representing the total share capital of the Han-woo medicine 5.36%. Even in the management of HSBC holdings into investment platforms, Zeng brothers also had a small bin holds 52.9% of the abundance of direct investment into equity. In addition to President John Yu Yuan Jiancheng medicine HSBC holds 34.7% equity investment into, other managers are rarely held interests, the holders of shares of HSBC as investors 1.24%.
Shenzhen, a private sector medical researcher Mr. Shaw said: the risk of technology drain. Medicine, said John Yu, president of Yuan Jiancheng core personnel management, production vice president of Long radium, R & D R & D Center, Vice President and Director of Maya Ping peptide, Liu Yu Deng Jun, vice president of marketing in the pharmaceutical industry has many years of peptide research and development, management and marketing experience, the company's grasp of product development and marketing played a key role. If the significant change in the core management company's production will adversely affect the business. Photographer / high fertility culture
No comments:
Post a Comment